

Director/PDMR Shareholding

RNS Number : 1866N

Novacyt S.A.

18 May 2020

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholdings

Paris, France and Camberley, UK - 18 May 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 15 May 2020, the following Directors purchased ordinary shares of €1/15 each in the Company (the "Ordinary Shares"):

Director	Title	Number of Ordinary Shares purchased	Price paid per Ordinary Share	Resultant beneficial holding	% of issued share capital
Graham Mullis	Chief Executive Officer	9,493	310p	61,631	0.09%
James Wakefield	Non-Executive Director & Chairman	20,000	304.9p	36,839	0.05%

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name Graham Mullis, Chief Executive Officer

2. Reason for the Notification

a) Position/status See 1(a) - classified as a PDMR of the Company

b) Initial notification/ Amendment Initial Notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name Novacyt S.A.
 - b) LEI 213800BWAC2BF295EG28
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 - a) Description of the Financial instrument, type of ordinary shares of €1/15 each instrument

Identification code	FR0010397232	
---------------------	--------------	--
 - b) Nature of the transaction Acquisition of Ordinary Shares
- c) Price(s) and volume(s)

	Price	Volume
	310 pence	9,493

N/A Single transaction as above
- d) Aggregated information:

· Aggregated volume	Price	Volume
· Price	310 pence	9,493
- e) Date of the transaction 15 May 2020
- f) Place of the transaction AIM

1. Details of the person discharging managerial responsibilities / person closely associated

- a) Name James Wakefield, Non-Executive Director & Chairman of the Board

2. Reason for the Notification

- a) Position/status See 1(a) - classified as PDMRs of the Company
- b) Initial notification/ Amendment Initial Notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name Novacyt S.A.
- b) LEI 213800BWAC2BF295EG28
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the Financial instrument, type of instrument	ordinary shares of €1/15 each	
Identification code	FR0010397232	
b) Nature of the transaction	Acquisition of Ordinary Shares	
c) Price(s) and volume(s)	Price	Volume
	a) 304.9 pence	20,000
	N/A single transaction as above	
Aggregated information:	Price	Volume
d) · Aggregated volume	a) 304.9p	20,000
· Price		
e) Date of the transaction	15 May 2020	
f) Place of the transaction	AIM	

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

FTI Consulting (International)

Victoria Foster Mitchell / Mary Whittow

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 47

arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHGPUAAAUPUUMR